← Leaderboards
Todd W Ridky
Stanford University
$5,236,268
Attributed
$5,236,268
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $796.5K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,236,268 · 6
By mechanism
R01$3,817,333 · 2
K08$597,645 · 1
R56$357,500 · 1
R41$299,998 · 1
F32$163,792 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Paul A Khavari$40,653,927
- Kavita Yang Sarin$886,696
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionMediatingTumorProteinsFutureSkinOncogenicGeneticPathway InteractionsSquamous Cell CarcinomaMalignant NeoplasmsTissuesKeratinocyteHuman TissueResponsePhysiologicalMalignant - DescriptorHomeostasisIn VivoNeoplasmsFundingMedicalMutationEpidermis
Grant awards (21)
Using Nonclassical Estrogen Signaling to Prevent Melanoma$419,353
R01 · FY2023 · CA · contact PI
Using Nonclassical Estrogen Signaling to Prevent Melanoma$424,200
R01 · FY2022 · CA · contact PI
Using Nonclassical Estrogen Signaling to Prevent Melanoma$438,974
R01 · FY2021 · CA · contact PI
Impact of Endogenous DOPA Signaling on Melanocyte Homeostasis and Melanoma Susceptibility$357,500
R56 · FY2021 · AR · contact PI
Using Nonclassical Estrogen Signaling to Prevent Melanoma$442,834
R01 · FY2020 · CA · contact PI
Using Nonclassical Estrogen Signaling to Prevent Melanoma$461,852
R01 · FY2019 · CA · contact PI
Development of GPER agonists as Cancer Therapeutics$299,998
R41 · FY2018 · CA · contact PI
Signaling Modulators in Epidermal Carcinogenesis$332,000
R01 · FY2016 · CA · contact PI
Signaling Modulators in Epidermal Carcinogenesis$332,000
R01 · FY2015 · CA · contact PI
Signaling Modulators in Epidermal Carcinogenesis$322,040
R01 · FY2014 · CA · contact PI
Signaling Modulators in Epidermal Carcinogenesis$312,080
R01 · FY2013 · CA · contact PI
Signaling Modulators in Epidermal Carcinogenesis$332,000
R01 · FY2012 · CA · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$119,529
K08 · FY2011 · AR · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$118,500
K08 · FY2010 · AR · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$1,029
K08 · FY2010 · AR · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$119,529
K08 · FY2009 · AR · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$119,529
K08 · FY2008 · AR · contact PI
Physiologic Function of RAS Effectors MEK 1/2 on Epidermal Differentiation$119,529
K08 · FY2007 · AR · contact PI
Ras Dependent Human Cutaneous Neoplasia$57,536
F32 · FY2005 · CA
Ras Dependent Human Cutaneous Neoplasia$54,352
F32 · FY2004 · CA
Ras Dependent Human Cutaneous Neoplasia$51,904
F32 · FY2003 · CA